Skip to main content
SpringerLink
Log in

Galantamine for Alzheimer’s Disease and Alzheimer’s Disease with Cerebrovascular Disease

  • Chapter
  • First Online:
Practical Pharmacology for Alzheimer’s Disease

Abstract

Despite numerous attempts to develop new classes of compounds for either the progression or symptomatic treatment of Alzheimer’s disease, there have been no successes to date. Hence, the mainstay of the treatment of mild-to-moderate Alzheimer’s disease (AD) remains the cholinesterase inhibitors. Despite the widespread use of these drugs, there is scant literature discussing the relative differences among these compounds and the practical consequences of those differences. Indeed, a recent review in a respected journal notes that “AD … responds only marginally and briefly to currently available drugs” (Bloom 2014). The purpose of this review article is to delineate the important properties that distinguish these compounds and the clinical implications of those differences. It will do so by largely focusing on donepezil, the most frequently prescribed cholinesterase inhibitor, and contrasting donepezil with galantamine, the cholinesterase inhibitor that differs the most in its mechanism of action within this class of compounds.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • AD 2000 Collaborative Group (2000) Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomized double-blind trial. Lancet 363:2105–2115

    Google Scholar 

  • Ametamey SM, Bruehlmeier M, Kneifel S et al (2002) PET studies of 18F-memantine in healthy volunteers. Nucl Med Biol 29:227–231

    Article  CAS  PubMed  Google Scholar 

  • Aracava Y, Periera EFR, Maelicke A et al (2005) Memantine blocks α7* nicotinic acetylcholine receptors more potently than N-methyl-D-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther 312:1195–1205

    Article  CAS  PubMed  Google Scholar 

  • Auchus AP, Brashear HR, Salloway S et al (2007) Galantamine treatment of vascular dementia: a randomized trial. Neurology 69:448–458

    Article  CAS  PubMed  Google Scholar 

  • Black S, Roman GC, Geldmacher DS et al (2003) Efficacy and tolerability of donepezil in vascular dementia. Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 34:2323–2332

    Article  CAS  PubMed  Google Scholar 

  • Black SE, Doody R, Li H et al (2007) Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 69:459–469

    Article  CAS  PubMed  Google Scholar 

  • Bloom G (2014) Amyloid β and tau. The trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71:505–508

    Article  PubMed  Google Scholar 

  • Brodaty H, Corey-Bloom J, Potocnik FCV et al (2005) Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer’s disease. Dement Geriatr Cogn Disord 20:120–132

    Article  CAS  PubMed  Google Scholar 

  • Buisson B, Bertrand D (1998) Open-channel blockers at the human α4β2 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 53:555–563

    CAS  PubMed  Google Scholar 

  • Bullock R, Touchon J, Bergman H et al (2005) Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Curr Med Res Opin 21:1317–1327

    Article  CAS  PubMed  Google Scholar 

  • Burns A, Rossor M, Hecker J et al (1999) The effects of donepezil in Alzheimer’s disease – results from a multinational trial. Dement Geriatr Cogn Disord 10:237–244

    Article  CAS  PubMed  Google Scholar 

  • Burns A, Bernabei R, Bullock R et al (2009) Safety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD study): a randomized, placebo-controlled, double-blind trial. Lancet Neurol 8:39–47

    Article  CAS  PubMed  Google Scholar 

  • Chen H, Huang X, Guo X et al (2010) Smoking duration, intensity, and risk of Parkinson’s disease. Neurology 74:878–884

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Davidsson P, Blennow K, Andreasen N et al (2001) Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer’s disease. Neurosci Lett 300:157–160

    Article  CAS  PubMed  Google Scholar 

  • Davis B, Sadik K (2006) Circadian cholinergic rhythms: implications for cholinesterase inhibitor therapy. Dement Geriatr Cogn Disord 21:120–129

    Article  PubMed  Google Scholar 

  • Doody RS, Geldmacher DS, Gordon B et al (2001) Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 58:427–433

    Article  CAS  PubMed  Google Scholar 

  • Dubois B, Chupin M, Croisile B et al (2012) Donepezil decreases rate of hippocampal atrophy in patients with prodromal Alzheimer’s disease. In: Poster presented at the international conference on Alzheimer’s disease, Paris, 16–21 July 2011

    Google Scholar 

  • Easton A, Sankaranarayanan S, Tanghe A et al (2013) Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer’s disease. Psychopharmacology (Berl) 230:279–289

    Article  CAS  Google Scholar 

  • Engedal K, Davis B, Richarz U et al (2012) Two galantamine titration regimens in patients switched from donepezil. Acta Neurol Scand 126:37–44

    Article  CAS  PubMed  Google Scholar 

  • Erkinjuntti T, Kurz A, Gauthier S et al (2002) Efficacy of galantamine in probably vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomized trial. Lancet 359:1283–1290

    Article  PubMed  Google Scholar 

  • Farlow MR, Cummings JL (2007) Effective pharmacologic management of Alzheimer’s disease. Am J Med 120:388–397

    Article  CAS  PubMed  Google Scholar 

  • Feldman H, Gauthier S, Hecker J et al (2001) A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 57:613–620

    Article  CAS  PubMed  Google Scholar 

  • Feldman HH, Ferris S, Winblad B et al (2007) Effect of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 6:501–512

    Article  CAS  PubMed  Google Scholar 

  • Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198

    Article  CAS  PubMed  Google Scholar 

  • Gandy S, Heppner FL (2013) Microglia as dynamic and essential components of the amyloid hypothesis. Neuron 78:575–576

    Article  CAS  PubMed  Google Scholar 

  • Gelinas I, Gautier L (1994) Disability assessment for dementia (DAD). http://www.dementia-assessment.com.au/function/. Accessed 1 Nov 2014

  • Gunnarsson MD, Lannfelt L, Ingelsson M et al (2014) High tau levels in cerebrospinal fluid predict rapid decline and increased dementia mortality in Alzheimer’s disease. Dement Geriatr Cogn Disort 37:196–206

    Article  Google Scholar 

  • Hager K, Baseman AS, Nye JS et al (2014) Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease. Neuropsychiatr Dis Treat 10:391–401

    PubMed Central  CAS  PubMed  Google Scholar 

  • Hashimoto M, Kazui H, Matsumoto K et al (2005) Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer’s disease? Am J Psychiatry 162:676–682

    Article  PubMed  Google Scholar 

  • Homma A, Imai Y, Tago H (2008) Donepezil treatment of patients with severe Alzheimer’s disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord 25:399–407

    Article  CAS  PubMed  Google Scholar 

  • Homma A, Nakamura Y, Saito T et al (2011) A placebo-controlled, double-blind, comparative study of galantamine hydrobromide in patients with Alzheimer-type dementia. Jap J Geriat Psychiat 22:333–345

    Google Scholar 

  • Howard RJ, Juszczak E, Ballard CG (2007) Donepezil for the treatment of agitation in Alzheimer’s disease. N Engl J Med 357:1382–1392

    Article  CAS  PubMed  Google Scholar 

  • Inestrosa NC, Alvarez A, Perez CA et al (1996) Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer’s fibrils: Possible role of the peripheral site of the enzyme. Neuron 16:881–891

    Article  CAS  PubMed  Google Scholar 

  • Jack CR, Petersen RC, Grundman M et al (2008) Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging 29:1285–1295

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Johannsen P, Salmon E, Hampel H et al (2006) Assessing therapeutic efficacy in a progressive disease. A study of donepezil in Alzheimer’s disease. CNS Drugs 20:311–325

    Article  CAS  PubMed  Google Scholar 

  • Kawamata J, Shimohama S (2011) Stimulating nicotinic receptors triggers multiple pathways attenuating cytotoxicity in models of Alzheimer’s and Parkinson’s diseases. J Alzheimers Dis 24:95–109

    CAS  PubMed  Google Scholar 

  • Kester MI, van der Vlies AE, Blankenstein MA et al (2009) CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology 73:1353–1358

    Article  CAS  PubMed  Google Scholar 

  • Kihara T, Sawada H, Nakamizo T et al (2004) Galantamine modulates nicotinic receptor and blocks Aβ-enhanced glutamate toxicity. Biochem Biophys Res Comm 325:976–982

    Article  CAS  PubMed  Google Scholar 

  • Krishnan KRR, Charles HC, Doraiswamy PM et al (2003) Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer’s disease. Am J Psychiatry 160:2003–2011

    Article  PubMed  Google Scholar 

  • Kuhl DE, Minoshima S, Frey KA et al (2000) Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol 48:391–395

    Article  CAS  PubMed  Google Scholar 

  • Kulkull WA (2001) The association between smoking and Alzheimer’s disease: effects of study design and bias. Biol Psychiatry 49:194–199

    Article  Google Scholar 

  • Kuryatov A, Onksen J, Lindstrom J (2008) Roles of accessory subunits in α4β2* nicotinic receptors. Mol Pharmacol 74:132–143

    Article  CAS  PubMed  Google Scholar 

  • Mao D, Perry DC, Yasuda RP et al (2008) The α4β2α5 nicotinic cholinergic receptor in rat brain is resistant to up-regulation by nicotine in vivo. J Neurochem 104:446–456

    CAS  PubMed  Google Scholar 

  • Mawuenyega KG, Sigurdson W, Ovod V et al (2010) Decreased clearance of CNS β-amyloid in Alzheimer’s disease. Science 330:1774

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Medical Economics Staff (2002) Physicians desk reference. Thompson PDR, Oradell

    Google Scholar 

  • Mohs RC, Doody RS, Morris JC et al (2001) A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57:481–488

    Article  CAS  PubMed  Google Scholar 

  • Nakamura Y, Imai Y, Shigeta M et al (2011) A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients. Dement Geriatr Cogn Disord Extra 1:163–179

    Article  Google Scholar 

  • Nordberg A, Darreh-Shori T, Peskind E et al (2009) Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr Alzheimers Res 6:4–14

    Article  CAS  Google Scholar 

  • Ohnishi A, Mihara M, Kamakura H et al (1993) Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy young and elderly subjects. J Clin Pharmacol 33:1086–1091

    Article  CAS  PubMed  Google Scholar 

  • Okonkwo OC, Alosco ML, Griffith R et al (2010) Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum. Arch Neurol 67:688–696

    Article  PubMed Central  PubMed  Google Scholar 

  • Periclou A, Ventura D, Rao N et al (2006) Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther 79:134–143

    Article  CAS  PubMed  Google Scholar 

  • Petersen R, Grundman M, Thomas R et al (2004) Donepezil and vitamin E as treatments for mild cognitive impairment. In: Presented at the international conference on Alzheimer’s disease, Philadelphia, 18 July 2004

    Google Scholar 

  • Petersen RC, Thomas RG, Grundman M et al (2005) Vitamin E and Donepezil for the treatment of mild cognitive impairment. N Engl J Med 352:2379–2388

    Article  CAS  PubMed  Google Scholar 

  • Pimlott SL, Piggott M, Owens J et al (2004) Nicotinic acetylcholine receptor distribution in Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, and vascular dementia: In vitro binding study using 5-[125 I]-A-85380. Neuropsychopharmacology 29:108–116

    Article  CAS  PubMed  Google Scholar 

  • Prnewswire.com (2012) www.Prnewswire.com/news-releases/lilly-announces-detailed-results-of-the-phase-3-solanezumab-expedition-studies-following-a-presentation-of-the-independent-analyses-by-the-alzheimers-disease-cooperative-study-adcs-1314411.html. Accessed 5 Nov 2012

  • Product Monograph (2008) Janssen-Ortho, Inc., Toronto

    Google Scholar 

  • Raskind MA, Peskind ER, Wessel T et al (2000) A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 54:2261–2268

    Article  CAS  PubMed  Google Scholar 

  • Rasmusen L, Yan B, Robillard A et al (2001) Effects of washout and dose-escalation periods on the efficacy, safety and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials. Clin Ther 23(Suppl A):A25–A30

    Article  CAS  PubMed  Google Scholar 

  • Rees T, Hammond PI, Soreq H et al (2003) Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol Aging 24:777–787

    Article  CAS  PubMed  Google Scholar 

  • Rockwood K, Mintzer J, Truyen L et al (2001) Effects of a flexible galantamine dose in Alzheimer’s disease: a randomized, controlled trial. J Neurol Neurosurg Psychiatry 71:589–595

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Rogers SL, Farlow MR, Doody RS et al (1998a) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 50:136–145

    Article  CAS  PubMed  Google Scholar 

  • Rogers SL, Doody RS, Mohs RC et al (1998b) Donepezil improves cognition and global function in Alzheimer disease. Arch Intern Med 158:1021–1031

    Article  CAS  PubMed  Google Scholar 

  • Roman GC, Salloway S, Black SE (2010) Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia. Differential effects by hippocampal size. Stroke 41:1213–1241

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Saab BJ, Roder JC (2011) Acute pharmacokinetics of memantine in the mouse. Pharmacology 88:284–287

    Article  CAS  PubMed  Google Scholar 

  • Samochocki M, Hoffle A, Fehrenbacher A et al (2003) Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305:1024–1036

    Article  CAS  PubMed  Google Scholar 

  • Sasaki S, Horie Y (2014) The effects of an uninterrupted switch from donepezil to galantamine without dose titration on behavioral and psychological symptoms of dementia in Alzheimer’s disease. Dement Geriatr Cogn Disord Extra 4:131–139

    Article  Google Scholar 

  • Scheltens P, Fox NC, Barkhof F et al (2004) Effect of galantamine treatment on brain atrophy as assessed by MRI in subjects with mild cognitive impairment. In: Poster presented at the 9th international conference on Alzheimer’s disease and related disorders, Philadelphia, 17–22 July 2004

    Google Scholar 

  • Schuff N, Suhy J, Goldman R et al (2011) An MRI substudy of a donepezil clinical trial in mild cognitive impairment. Neurobiol Aging 32:2318.e31–2318.e41

    Article  CAS  Google Scholar 

  • Singh G, Thomas SK, Arcona S et al (2005) Treatment persistency with rivastigmine and donepezil in a large state Medicaid program. J Am Geriatr Soc 53:1269–1270

    Article  PubMed  Google Scholar 

  • Skillback T, Zetterberg H, Blennow K et al (2013) Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples. Alzheimers Res Ther 5:47–56

    Article  PubMed Central  PubMed  Google Scholar 

  • Stahl SM, Markowitz JS, Gutterman EM et al (2003) Co-use of donepezil and hypnotics among Alzheimer’s disease patients living in the community. J Clin Psychiatry 64:466–472

    Article  CAS  PubMed  Google Scholar 

  • Stahl SM, Markowitz JS, Papadopoulos G et al (2004) Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer’s disease. Curr Med Res Opin 20:517–524

    Article  CAS  PubMed  Google Scholar 

  • Takada-Takatori Y, Kume T, Sugimoto M et al (2006) Neuroprotective effects of galanthamine and tacrine against glutamate neurotoxicity. Eur J Pharmacol 549:19–26

    Article  CAS  PubMed  Google Scholar 

  • Takada-Takatori Y, Kume T, Izumi Y et al (2009) Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor up-regulation. Biol Pharm Bull 32:318–324

    Article  CAS  PubMed  Google Scholar 

  • Takata K, Kitamura Y, Saeki M et al (2010) Galantamine-induced amyloid-β clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem 285:40180–40191

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Tariot PN, Solomon PR, Morris JC et al (2000) A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 54:2269–2276

    Article  CAS  PubMed  Google Scholar 

  • Tariot PN, Cummings JL, Katz IR et al (2001) A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc 49:1590–1599

    Article  CAS  PubMed  Google Scholar 

  • Texido L, Ros E, Martin-Satue M et al (2005) Effect of galantamine on the human α7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity. Br J Pharmacol 145:672–678

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Tiseo PJ, Rogers SL, Friedhoff LT (1998) Pharmacokinetic and pharmacodynamics profile of donepezil HCl following evening administration. Br J Clin Pharmacol 46(Suppl 1):13–18

    PubMed Central  CAS  PubMed  Google Scholar 

  • Unger C, Svedberg MM, Yu W-F et al (2006) Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APPswe) transgenic mice. J Pharmacol Exp Ther 317:30–36

    Article  CAS  PubMed  Google Scholar 

  • Vanmechelen E, Andreasen N, Minthon L et al (2001) Effects of cholinesterase inhibitors on Alzheimer’s disease biomarkers. Innogenetics, Ghent

    Google Scholar 

  • Wallin AK, Blennow K, Zetterberg H et al (2010) CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 74:1531–1537

    Article  CAS  PubMed  Google Scholar 

  • Wang L, Harms MP, Staggs JM et al (2010) Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease. Arch Neurol 67:99–106

    Article  PubMed Central  PubMed  Google Scholar 

  • Wilcock G, Howe I, Coles H et al (2003) A long-term comparison of galantamine and donepezil in the treatment of Alzheimer’s disease. Drugs Aging 20:777–789

    Article  CAS  PubMed  Google Scholar 

  • Wilkinson D, Doody R, Helme R et al (2003) Donepezil in vascular dementia. A randomized, placebo-controlled study. Neurology 61:479–486

    Article  CAS  PubMed  Google Scholar 

  • Wilkinson DG, Howe I, the GAL-GBR-1 Study Group (2005) Switching from donepezil to galantamine: a double-blind study of two wash-out periods. Int J Geriat Psychiatr 20:489–491

    Article  Google Scholar 

  • Winblad B, Engedal K, Soininen H et al (2001) a 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57:489–495

    Article  CAS  PubMed  Google Scholar 

  • Winblad B, Kilander L, Eriksson S et al (2006) Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet 367:1057–1065

    Article  CAS  PubMed  Google Scholar 

  • Winblad B, Gauthier S, Scinto L et al (2008) Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 70:2024–2035

    Article  CAS  PubMed  Google Scholar 

  • Zhang B, Gaiteri C, Bodea L-G et al (2013) Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease. Cell 153:707–720

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. New York, New York, USA

    Kenneth L. Davis

Authors
  1. Kenneth L. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Davis, K.L. (2016). Galantamine for Alzheimer’s Disease and Alzheimer’s Disease with Cerebrovascular Disease. In: Practical Pharmacology for Alzheimer’s Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-26206-2_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26206-2_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-26204-8

  • Online ISBN: 978-3-319-26206-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation